-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
-
Summary
-
Lineage Cell Therapeutics, Inc. quarterly/annual Revenue from Contract with Customer, Excluding Assessed Tax history and change rate from 2017 to Q3 2025.
- Lineage Cell Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the quarter ending 30 Sep 2025 was $3.68M, a 2.59% decline year-over-year.
- Lineage Cell Therapeutics, Inc. Revenue from Contract with Customer, Excluding Assessed Tax for the twelve months ending 30 Sep 2025 was $10.8M, a 24.1% increase year-over-year.
- Lineage Cell Therapeutics, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2024 was $9.5M, a 6.19% increase from 2023.
- Lineage Cell Therapeutics, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2023 was $8.95M, a 39.2% decline from 2022.
- Lineage Cell Therapeutics, Inc. annual Revenue from Contract with Customer, Excluding Assessed Tax for 2022 was $14.7M, a 239% increase from 2021.
Revenue from Contract with Customer, Excluding Assessed Tax, Trailing 12 Months (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, Quarterly (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Quarterly Change (%)
Revenue from Contract with Customer, Excluding Assessed Tax, Annual (USD)
Revenue from Contract with Customer, Excluding Assessed Tax, YoY Annual Change (%)